louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04952922: Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer
Official title: Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Recurrent Oropharynx Carcinoma
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: Imperial College London
First posted: 2021-07-07
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a confirmed diagnosis of recurrent, residual or new primary oropharyneal cancer in a previously irradiated field.

Brief summary: The purpose of this research project is to measure changes in communication, swallowing and quality of life and individual patient priorities which may happen over time in patients with a diagnosis of recurrent head and neck cancer, specifically recurrent cancer (cancer which has returned after previous treatment) of the back of the throat, the tonsils and/or the base of tongue (recurrent oropharyngeal cancer) and what it is like for patients and their significant others to experience these changes over time.


Eligibility criteria: Inclusion Criteria:

* Adult (aged 18 years or over) competent to provide consent
* Have a diagnosis of recurrent OPC
* Have adequate linguistic and cognitive function to participate in interview
* English speaking

Exclusion Criteria:

* Any previous medical condition, other than HNC, which has a known impact on communication/ swallowing (Parkinson's Disease, Multiple Sclerosis, cerebral vascular accident (CVA)

Primary outcomes:
measure: Patient reported swallowing related quality of life
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
Study officials:
References:
Clinical trial NCT00461422: Early Follicular Supplementation of Ganirelix in IVF 2004
Official title: Early Follicular GnRH Antagonist Supplementation Improves Fertilization and Embryo Cleavage Rates in IVF-ET GnRH Antagonist Cycles
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
IVF Treatment
Keywords: IVF
GnRH antagonist
Lead sponsor: The Baruch Padeh Medical Center, Poriya
Sponsor class: OTHER_GOV
Collaborators: name: Organon
First posted: 2007-04-18
Enrollment: 50
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results

Detailed description: GnRH antagonist offers many advantages when used in IVF-ET treatment, however, it is suspected to yield lower pregnancy rate when compared with the long GnRH agonist protocol.

Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results.

Consecutive patients are prospectively enrolled and randomly assigned to the study and control groups. Patients with low ovarian reserve or with uterine distortion are excluded from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group are also treated with additional GnRH antagonist 0.25 mg/day on day 1, 2 and 3 of the menstrual cycle.

Eligibility criteria: Inclusion Criteria:

* infertility
* IVF candidate
* failure of previous IVF attempt

Exclusion Criteria:

* low ovarian reserve
* untreated distortion of uterine cavity
* medical contraindication for IVF treatment

Primary outcomes:
measure: pregnancy rates
timeFrame: one cycle
Secondary outcomes:
measure: differences in hormonal levels
timeFrame: one cycle
measure: differences in the basic treatment doses
timeFrame: one cycle
measure: oocyte counts
timeFrame: one cycle
measure: fertilization rate
timeFrame: one cycle
measure: cleavage rate
timeFrame: one cycle
Other outcomes:
Locations:
city: Tiberias
country: Israel
facility: The Baruch Padeh medical center, Poriya
Study officials:
affiliation: The Ministry of Health, Israel
name: Yohnny S Younis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06254222: Ethical Crossroads in Nursing Education
Official title: Ethical Crossroads in Nursing Education: Mapping the Terrain of Ethical Sensitivity and Professional Identity Among Nursing Students
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Ethics, Narrative
Professional Identity Formation
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 224
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Nursing students from all levels

Brief summary: In conclusion, understanding the variables influencing ethical decision-making among nursing students is crucial for developing interventions to minimize moral distress and promoting their ability to cope with ethical issues and dilemmas. While acknowledging the existence of ethical challenges, it is noteworthy that there is a dearth of studies investigating the intricate relationship between ethical sensitivity and the development of professional identity among nursing students. This research aims to fill this gap, advancing our understanding and providing valuable insights for shaping effective educational practices. In this improvement, the research problem is clearly stated: the need to explore the relationship between ethical sensitivity and professional identity among nursing students, with a call for further research to bridge the existing gap.

In light of the identified research gap regarding the correlation between ethical sensitivity and the development of professional identity among nursing students, this study seeks to answer the following question: How does ethical sensitivity influence the formation of professional identity in nursing students within the context of contemporary healthcare environments, characterized by evolving technology and complex health systems?


Eligibility criteria: Inclusion Criteria:

- Participants will be recruited from diverse online communities, including platforms such as Facebook, WhatsApp, and Telegram. The decision to utilize these social media channels is based on their extensive usage within the target population, ensuring effective outreach and active participation. The undergraduate nursing students at the college are expected to establish dedicated social media groups for each academic level.

Exclusion Criteria:

* Students not from nursing background education

Primary outcomes:
measure: Moral Sensitivity Questionnaire
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
measure: Professional Identity Questionnaire
timeFrame: through study completion, an average of 6 months
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Faculty of Nursing
state: Dakhlyia
Study officials:
References:
Clinical trial NCT02882022: Evaluating Changes in Middle Ear Pressure Caused by CPAP
Official title: Evaluating Changes in Middle Ear Pressure Caused by CPAP
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Eustachian Tube Disorder
Keywords: Eustachian tube dysfunction
Audiometry
Lead sponsor: University of Virginia
Sponsor class: OTHER
First posted: 2016-08-29
Enrollment: 0
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is an investigation into the effect that CPAP has on the pressure in the middle ear. It will evaluate the middle ear pressure and ear drum appearance at multiple levels of CPAP pressure delivered via a full face mask. These measurements will be used to determine optimal levels of CPAP to affect individual's middle ear pressure, particularly those with negative middle ear pressure due to Eustachian tube dysfunction.


Eligibility criteria: Inclusion Criteria:

* Age \>18
* No use of CPAP within past 30 days
* Individuals presenting to the UVA otolaryngology clinic who are otherwise healthy

Exclusion Criteria:

* Pre-existing cardiopulmonary disease that presents a risk with CPAP use
* Inability to tolerate CPAP
* Recent otologic surgery

Primary outcomes:
measure: Tympanometry
timeFrame: 1 minute
Secondary outcomes:
measure: Subjective sensation
timeFrame: 1 minute
measure: Subjective symptom score
timeFrame: 1 minute
measure: Otoscopy
timeFrame: 1 minute
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
References:
citation: Akbulut S, Demir MG, Salepci BM, Gungor GA, Demir N, Berk D, Cakan D. Efficacy of continuous positive airway pressure on middle ear atelectasis: A double-blind placebo-controlled clinical trial. Laryngoscope. 2016 Jul;126(7):1649-55. doi: 10.1002/lary.25735. Epub 2015 Oct 20.
citation: Aksoy F, Yildirim YS, Ozturan O, Veyseller B, Cuhadaroglu C. Eustachian tube function in patients receiving continuous positive airway pressure treatment for sleep apnea syndrome. J Otolaryngol Head Neck Surg. 2010 Dec;39(6):752-6.
citation: Drake-Lee AB, Casey WF, Ogg TW. Anaesthesia for myringotomy. The effect of nitrous oxide and intermittent positive pressure ventilation in children with secretory otitis media. Anaesthesia. 1983 Apr;38(4):314-8. doi: 10.1111/j.1365-2044.1983.tb10451.x.
citation: Lin FY, Gurgel RK, Popelka GR, Capasso R. The effect of continuous positive airway pressure on middle ear pressure. Laryngoscope. 2012 Mar;122(3):688-90. doi: 10.1002/lary.22442. Epub 2012 Jan 17.
citation: Sivri B, Sezen OS, Akbulut S, Coskuner T. The effect of continuous positive airway pressure on middle ear pressure. Laryngoscope. 2013 May;123(5):1300-4. doi: 10.1002/lary.23896. Epub 2013 Apr 2.
Clinical trial NCT00789022: Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Schizophrenia
Schizophreniform
Schizoaffective Disorder
Brief Psychotic Episode
Keywords: First-Psychotic-Episode (FPE)
Glutamatergic system
Glycine
D-Serine
Oxytocin
Estrogen
Lead sponsor: Shalvata Mental Health Center
Sponsor class: OTHER
First posted: 2008-11-11
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized patients First degree ralatives Healthy subjects from the community

Brief summary: The goal of our research is to check the levels of D-Serine, Glycine, and other Glutamatergic amino acids, in patients with First Psychotic Episode (FPE). These patients are in the early stage of the disease, treated with neuroleptics for short periods of time, and are usually hospitalized for the first time. The hypothesis of the research is that we will find low levels of Glycine and D-Serine in these patients. Following an Anti-psychotic treatment we will expect these levels to return to the norm, and that this correction will be accompanied by a reduction of positive and negative symptoms.

In addition, we will check the D-Serine and Glycine levels in the plasma of first degree relatives of the patients and a group of healthy subjects. The results of this study might support the hypothesis that the Glutamatergic system in involved in the pathology of Schizophrenia from it's early stages.

In addition, we will check the levels of Oxytocin and Estrogen in the plasma of patients in FPE. Our hypothesis is that we will find low levels of Estrogen and High levels of Oxytocin in this group of patients. The results of the study might support the hypothesis that Estrogen and Oxytocin are involved in the pathology of Schizophrenia from it's early stages.


Eligibility criteria: Inclusion Criteria:

* Subjects between 18-60 years
* Clinical Diagnosis of Schizophrenia, Schizophreniphorm disorder, Schizoaffective Disorder, Brief esychotic episode

Exclusion Criteria:

* two years or more of positive symptoms
* Neuroleptic treatment for more then twe weeks in the prior month, or for more then six weeks at any time.
* Drug induced psychotic episode

Primary outcomes:
measure: Glycine and D-Serine levels in the plasma.
timeFrame: 6-8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Hod Hasharom
country: Israel
facility: Shalvata Medical Center
Study officials:
References:
Clinical trial NCT05599022: Randomized Assessment of TcMS for VT Storm
Official title: Randomized Assessment of the Efficacy of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ventricular Tachycardia
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2022-10-31
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Three-arm randomized clinical trial comparing two strategies of TcMS to sham stimulation in patients with VT storm. The hypothesis of the study is that TcMS will reduce the burden of VT in the 24 hours after randomization compared to sham stimulation and that TcMS with theta burst stimulation (TBS) will be more effective at reducing VT burden than low frequency TcMS.


Eligibility criteria: Inclusion Criteria:

* ≥3 episodes of sustained VT or appropriate ICD therapies within 24 hours despite the use of at least one antiarrhythmic drug

Exclusion Criteria:

* Plan for catheter ablation of VT in the next 24 hours
* Pregnancy
* Contraindication to TcMS (i.e. implantable ventricular assist device, metal implanted in the head or neck \[except the mouth\], implanted medication pumps, cochlear implant, implanted brain stimulator, ocular implant, history of malignancy in the neck)

Primary outcomes:
measure: VT Burden (24 hours)
timeFrame: 24 hours after randomization
Secondary outcomes:
measure: VT burden (72 hours)
timeFrame: 72 hours after randomization
measure: Freedom from VT
timeFrame: 24 hours after randomization
measure: Blood Pressure
timeFrame: Immediately before and after stimulation
measure: Heart Rate
timeFrame: Immediately before and after stimulation
measure: Pain
timeFrame: Immediately after stimulation
measure: Lead sensing
timeFrame: Immediately before and after stimulation
measure: Lead threshold
timeFrame: Immediately before and after stimulation
measure: Lead impedance
timeFrame: Immediately before and after stimulation
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01491022: A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Official title: A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Parkinson's Disease
Keywords: parkinson's
gait dysfunction
ampyra
4-aminopyridine
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Acorda Therapeutics
First posted: 2011-12-13
Enrollment: 22
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple sclerosis. There are multiple studies to suggest that persons with multiple sclerosis benefit from this medication and have major improvements in gait after taking this medication. However, this medication was never studied in Parkinson's disease. This study aims to learn about possible benefits of AMPYRA in Parkinson's disease (PD).

Detailed description: Subjects with Parkinson's disease will be randomly assigned to two groups. One group will receive Ampyra first for 4 weeks, followed by 2 weeks break and than 4 weeks placebo while the second group will first receive placebo and then Ampyra.

Eligibility criteria: Inclusion Criteria:

* Idiopathic PD with stage Hoehn and Yahr Stage\>2-3 and with gait freezing or postural instability.
* On stable dosage dopamine agonist/levodopa, and expected to remain on the same dosage of treatment for the duration of study
* Age less than 80, onset of disease at age more than 45.
* Able to give consent

Exclusion Criteria:

* Past medical history of seizures,
* History of renal insufficiency,
* History of cardiac arrhythmia,
* Severe arthritis,
* Women of childbearing potential,
* Cognitive impairment
* Age more than 80.
* PD patients stage 4 H\&Y
* PD patient with recent introduction of dopamine agonist or IMAO B
* PD patients participating in other studies

Primary outcomes:
measure: Change in Velocity
timeFrame: baseline and 4 weeks
Secondary outcomes:
measure: United Parkinson's Disease Rating Scale Score(UPDRS) ,
timeFrame: 4 weeks
measure: Freezing of Gait Questionnaire (FOGQ)
timeFrame: 4 weeks
measure: Timed Up and Go (TUG) Score
timeFrame: 4 weeks
measure: Timed 25-foot Walk Test (T25FW)
timeFrame: 4 weeks
measure: Change in Stride Legth
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Corneliu Luca
role: STUDY_CHAIR
References:
Clinical trial NCT01799122: Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Stress Urinary Incontinence
Official title: Randomized Clinical Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Surgical Management of Stress Urinary Incontinence
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Stress Urinary Incontinence
Urethral Sling Surgery
Lead sponsor: University of Manitoba
Sponsor class: OTHER
First posted: 2013-02-26
Sex: FEMALE
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Primary purpose: TREATMENT

Brief summary: Randomized comparison of two surgeries for the treatment of female stress urinary incontinence.


Eligibility criteria: Inclusion Criteria:

* women with stress urinary incontinence with a positive cough test
* patient request surgery for treatment

Exclusion Criteria:

* prodominantely overactive bladder
* previous failed procedure
* MUCP \<20 cm H2O
* presence of vaginal prolapse \> stage 1
* voiding dysfunction (PVR\>100 mL)

Primary outcomes:
measure: Cough test at one year from surgery
timeFrame: One year
Secondary outcomes:
measure: Subjective symptoms, QOL questionaires
timeFrame: 1 & 2 years post surgery
Other outcomes:
Locations:
city: Winnipeg
country: Canada
facility: Ken Maslow
state: Manitoba
Study officials:
References:
Clinical trial NCT03322722: Implementation of a Tool on Alimentary Empowerment in New-born Baby
Official title: Implementation of a Tool on Alimentary Empowerment in New-born Baby
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neonatal Feeding Disorder
Lead sponsor: Fondation Hôpital Saint-Joseph
Sponsor class: OTHER
First posted: 2017-10-26
Enrollment: 87
Sex: ALL
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: every baby born before 37 weeks of pregnancy between january 2017 and end of march 2017

Brief summary: The alimentation of the premature newborn children is one of main thing concerning of nurses and pediatricians in neonatology. The absence of common tool of evaluation of the children cause a great discrepancy in prescriptions and the practices of the nursing.The aim of this study is to estimate the improvement of the food empowerment of the premature newborn children after the introduction of a help tool at the food progress which allows to fit the prescription of food(supply) to the capacities of the newborn child.

Detailed description: If the importance of feeding premature newborns is a central concern during their management, the absence of an evaluation tool leads to a great disparity in their implementation (particularly marked by at regular times by the care teams), which can eventually lead to oral disorders. The possibility of an assessment of the newborn's skills could allow a homogenization of therapeutic proposals and thus a potentially faster progression of dietary independence of the newborn. This method could also encourage parental involvement in feeding care. The objective of the study is to evaluate the impact of a tool to help food progression on food autonomy.

Eligibility criteria: Inclusion Criteria:

* born before 37 weeks of pregnancy
* hospitalized in GHPSJ neonatology
* Predictable duration of hospitalization of at least 7 days

Exclusion Criteria:

* parents not speaking french language
* new borm with complication du to his prematurity

Primary outcomes:
measure: Age of prematurity of the newborn child
timeFrame: delivery date
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Groupe Hospitalier Paris Saint Joseph
state: Ile-de-France
Study officials:
affiliation: Fondation Hôpital Saint-Joseph
name: SUILS Hélène, MD
role: PRINCIPAL_INVESTIGATOR
References: